Nonmetastatic Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Nonmetastatic Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-06-03FDA Approved: NUBEQA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved Bayer's supplemental application for NUBEQA (darolutamide), expanding or updating its labeling related to nonmetastatic castrat…
-
FDA approval · 2023-10-13FDA Approved: NUBEQA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for NUBEQA (darolutamide) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2021-01-07FDA Approved: NUBEQA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for NUBEQA (darolutamide) filed by Bayer, updating the labeling for its use in nonmetastatic cas…